RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia

Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures.
Financing will advance a potential once-daily oral treatment designed to restore blood vessel stability in HHT, a serious inherited bleeding disorder with no approved therapies.
periSCOPE platform supports pipeline expansion across vascular diseases associated with vascular instability.

Naarden, the Netherlands, 6 October 2026 – RougeTx, a preclinical-stage biotechnology company developing first-in-class disease-modifying therapies designed to restore vascular integrity by targeting pericyte dysfunction, today announced its launch with a $58 million Series A financing. The round was co-led by founding investor BioGeneration Ventures (BGV) with Angelini Ventures, together with EIB (European Investment Bank) co-investment facility Aurea, and Kurma Partners, with further participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest, and Kerna Ventures.

Locations